About this event

  • Date and time Tue 17 May 2022 from 5:45pm to 8:00pm
  • Location Royal Society of Medicine
  • Organised by Public Engagement Programme

The 2022 Stevens lecture will see Professor James Larkin, Consultant Medical Oncologist from The Royal Marsden Hospital in London, provide an insightful presentation into the looming reality of curing metastatic solid tumours with immune checkpoint inhibitors and the possible outcomes of this prospect for millions of patients around the world. 

In the last 15 years, immune checkpoint inhibitors have been developed clinically for the treatment of cancer and these drugs are approved for the treatment of a number of different tumour types. In certain types of cancer such as melanoma, outcomes have been transformed and the possibility of cure of metastatic disease appears to be a realistic prospect.

Can't make it to London? You can live stream this lecture from anywhere. Click here to book your place.

Follow us on:

Key speakers

Professor James Larkin

Consultant Medical Oncologist who specialises in the treatment of melanoma and cancers of the kidney, The Royal Marsden Hospital

Speaker's biography

Professor Larkin grew up in North Cornwall before taking a first in Natural Sciences from Cambridge University. He undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008.


His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies.
He is a past Senior Clinical Advisor to CRUK, National Institute for Health Research (NIHR) National Specialty Lead for Early Phase Oncology Trials, as well as past Chair of the NCRI Renal Cancer Clinical Studies Group, The Royal Marsden/ICR Committee for Clinical Research and the CRUK Clinical Research Monitoring Panel. He is currently Vice-Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at The Royal Marsden/ICR Biomedical Research Centre. In 2018 he was elected as a Fellow of the Academy of Medical Sciences. Since 2019 he has been Vice-Chair of the Medical Oncology Specialist Advisory Committee for the Joint Royal Colleges of Physicians Training Board and in 2020 he was appointed as an NIHR Senior Investigator.


He serves as a medical advisor to the patient advocacy group Melanoma UK, as a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.


View the programme

Curing metastatic solid tumours with immune checkpoint inhibitors: A reality in 2022?

Professor James Larkin, Consultant Medical Oncologist who specialises in the treatment of melanoma and cancers of the kidney, The Royal Marsden Hospital

Drinks reception


Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom

Special rates for difficult times  

The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s weekly COVID-19 Series webinars remain free of charge, while there will be small charges to register for other online education. These fees enable the RSM to continue its programme of activities and apply during the course of the pandemic. 

Registration for this lecture will close 24 hours prior to the start time.

If UK government guidelines and restrictions change, the format of this event will be updated to comply, and all delegates will be notified via email.